Literature DB >> 8102723

Correction of Duncan's syndrome by allogeneic bone marrow transplantation.

L L Williams1, C M Rooney, M E Conley, M K Brenner, R A Krance, H E Heslop.   

Abstract

Duncan's syndrome (X-linked lymphoproliferative disorder) is a fatal immunodeficiency syndrome of unknown aetiology and without cure. We show that allogeneic bone marrow transplantation can correct the lethal immune deficits in a patient with this syndrome. We suggest that the primary abnormality in Duncan's syndrome is in bone-marrow derived cells.

Entities:  

Mesh：

Year:  1993        PMID： 8102723     DOI： 10.1016/0140-6736(93)91413-g

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  5 in total

Review 1.  Stem cell transplantation for immunodeficiency.

Authors:  A Fischer; E Haddad; N Jabado; J L Casanova; S Blanche; F Le Deist; M Cavazzana-Calvo
Journal:  Springer Semin Immunopathol       Date:  1998

2.  Prenatal diagnosis of X linked lymphoproliferative disease using multiplex polymerase chain reaction.

Authors:  V Schuster; S Seidenspinner; H W Kreth
Journal:  J Med Genet       Date:  1995-09       Impact factor: 6.318

3.  Molecular genetic haplotype segregation studies in three families with X-linked lymphoproliferative disease.

Authors:  V Schuster; S Seidenspinner; T Grimm; W Kress; S Zielen; M Bock; H W Kreth
Journal:  Eur J Pediatr       Date:  1994-06       Impact factor: 3.183

4.  Frequent mutations in SH2D1A (XLP) in males presenting with high-grade mature B-cell neoplasms.

Authors:  J T Sandlund; S A Shurtleff; M Onciu; E Horwitz; W Leung; V Howard; R Rencher; M E Conley
Journal:  Pediatr Blood Cancer       Date:  2013-04-15       Impact factor: 3.167

5.  Intact antigen presentation for Epstein-Barr virus (EBV)-specific CTL by a lymphoblastoid cell line established from a patient with severe chronic active EBV infection.

Authors:  H Kimura; I Tsuge; S Imai; M Yamamoto; K Kuzushima; T Osato; T Morishima
Journal:  Med Microbiol Immunol       Date:  1995-08       Impact factor: 3.402
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.